In addition to the well-known nuclear progesterone receptors (PRA and PRB), a class of non-nuclear has lately been introduced and partly characterized (mPR and PGRMC). However, the knowledge of their pharmacological effect in vivo is virtually unknown. This project aims to find substances that can be used for specific signaling through the non-genomic receptors, thereby avoid adverse effects from activation of nuclear receptors.
Publications:
Inhibition of ABCC5-mediated cGMP transport by progesterone, testosterone and their analogues (2021)
Expression of nuclear progesterone receptors (nPR), membrane progesterone receptors (mPR) and progesterone receptor membrane components (PGRMC) in the human endometrium after 6 months levonorgestrel low dose intrauterine therapy (2020)
Data on RT-qPCR assay of nuclear progesterone receptors (nPR), membrane progesterone receptors (mPR) and progesterone receptor membrane components (PGRMC) from human uterine endometrial tissue and cancer cells of the uterine cervix (2020)
MCF-7 Cell Apoptosis and Cell Cycle arrest - Non-genomic Effects of Progesterone and Mifepristone (RU-486) (2010)
High concentrations of progesterone and mifepristone mutually reinforce cell cycle retardation and induction of apoptosis (2009)
Non-genomic cell growth inhibition by progesterone. Cell cycle retardation and induction of cell death (2004)
Non-genomic effects of progestins - Inhibition of cell growth and increased intracellular levels of cyclic nucleotides (2003)
Cyclic AMP Stimulates the Cyclic GMP Egression Pump in Human Erythrocytes: Effects of Probenecid, Verapamil, Progesterone, Theophylline, IBMX, Forskolin, and Cyclic AMP on Cyclic GMP uptake and Association to Inside-Out Vesicles (1998)
Rapid non-genomic and concentration-dependent effects of progesterone in C4-I cells on the proposed tumor marker: Ratio between extracellular cGMP and cAMP levels (1995)